Aura Biosciences Inc

NASDAQ:AURAUnited States

Aura Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing precision immunotherapies to treat solid tumors designed to preserve the function of the afflicted organ with cancer. It is developing a pipeline of virus-like drug conjugates (VDCs), a class of drugs with a dual mechanism of action, that promote cancer cell death by both the delivery of the cytotoxic payload to generate acute necrosis and activation of a secondary immune mediated response. Its lead candidate, bel-sar, is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. Bel-sar consists of a human papillomavirus (HPV)-derived virus-like particle (VLP), conjugated to hundreds of infrared laser-activated molecules. It is evaluating the bel-sar in a Phase III CoMpass trial for the first line treatment of early-stage choroidal melanoma.

Contact Information

Headquarters

80 Guest StreetBOSTON, MA, United States 01235

Phone

617-500-8864

Fax

302-655-5049

Executives

Independent Chairman of the Board

David Johnson

President, Chief Executive Officer, Director

Elisabet de los Pinos

Chief Financial Officer

Julie Feder

Chief Technology Officer

Mark Plavsic

General Counsel, Company Secretary

Conor Kilroy